Literature DB >> 25790165

The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.

Sien Braat1, Charlotte D'Hulst1,2, Inge Heulens1, Silvia De Rubeis3,4, Edwin Mientjes5, David L Nelson6, Rob Willemsen5, Claudia Bagni3,7, Debby Van Dam8, Peter P De Deyn8,9,10, R Frank Kooy1.   

Abstract

Previous research indicates that the GABAAergic system is involved in the pathophysiology of the fragile X syndrome, a frequent form of inherited intellectual disability and associated with autism spectrum disorder. However, the molecular mechanism underlying GABAAergic deficits has remained largely unknown. Here, we demonstrate reduced mRNA expression of GABAA receptor subunits in the cortex and cerebellum of young Fmr1 knockout mice. In addition, we show that the previously reported underexpression of specific subunits of the GABAA receptor can be corrected in YAC transgenic rescue mice, containing the full-length human FMR1 gene in an Fmr1 knockout background. Moreover, we demonstrate that FMRP directly binds several GABAA receptor mRNAs. Finally, positive allosteric modulation of GABAA receptors with the neurosteroid ganaxolone can modulate specific behaviors in Fmr1 knockout mice, emphasizing the therapeutic potential of the receptor.

Entities:  

Keywords:  FMRP mRNA target; Fmr1 knockout mouse; GABAA receptor; fragile X syndrome; ganaxolone; targeted therapy

Mesh:

Substances:

Year:  2015        PMID: 25790165      PMCID: PMC4827888          DOI: 10.4161/15384101.2014.989114

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  44 in total

Review 1.  Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.

Authors:  Gary J Bassell; Stephen T Warren
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

Review 2.  Molecular mechanisms of fragile X syndrome: a twenty-year perspective.

Authors:  Michael R Santoro; Steven M Bray; Stephen T Warren
Journal:  Annu Rev Pathol       Date:  2011-10-10       Impact factor: 23.472

3.  Fragile X mice develop sensory hyperreactivity to auditory stimuli.

Authors:  L Chen; M Toth
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 4.  Fragile X syndrome neurobiology translates into rational therapy.

Authors:  Sien Braat; R Frank Kooy
Journal:  Drug Discov Today       Date:  2014-02-07       Impact factor: 7.851

5.  A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model.

Authors:  Laetitia Davidovic; Vincent Navratil; Carmela M Bonaccorso; Maria Vincenza Catania; Barbara Bardoni; Marc-Emmanuel Dumas
Journal:  Genome Res       Date:  2011-09-07       Impact factor: 9.043

6.  The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif.

Authors:  C Schaeffer; B Bardoni; J L Mandel; B Ehresmann; C Ehresmann; H Moine
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

7.  Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse.

Authors:  Abdeslem El Idrissi; Xiao-Hua Ding; Jason Scalia; Ekkhart Trenkner; W Ted Brown; Carl Dobkin
Journal:  Neurosci Lett       Date:  2004-12-23       Impact factor: 3.046

Review 8.  Fragile X Syndrome: from molecular pathology to therapy.

Authors:  Thomas Maurin; Samantha Zongaro; Barbara Bardoni
Journal:  Neurosci Biobehav Rev       Date:  2014-01-22       Impact factor: 8.989

9.  A novel function for fragile X mental retardation protein in translational activation.

Authors:  Elias G Bechara; Marie Cecile Didiot; Mireille Melko; Laetitia Davidovic; Mounia Bensaid; Patrick Martin; Marie Castets; Philippe Pognonec; Edouard W Khandjian; Hervé Moine; Barbara Bardoni
Journal:  PLoS Biol       Date:  2009-01-20       Impact factor: 8.029

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  39 in total

1.  Postsynaptic FMRP Regulates Synaptogenesis In Vivo in the Developing Cochlear Nucleus.

Authors:  Xiaoyu Wang; Diego A R Zorio; Leslayann Schecterson; Yong Lu; Yuan Wang
Journal:  J Neurosci       Date:  2018-06-27       Impact factor: 6.167

2.  Widespread Alterations in Translation Elongation in the Brain of Juvenile Fmr1 Knockout Mice.

Authors:  Sohani Das Sharma; Jordan B Metz; Hongyu Li; Benjamin D Hobson; Nicholas Hornstein; David Sulzer; Guomei Tang; Peter A Sims
Journal:  Cell Rep       Date:  2019-03-19       Impact factor: 9.423

Review 3.  Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2017-11-15       Impact factor: 4.030

Review 4.  Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops.

Authors:  Caitlin Mullins; Gord Fishell; Richard W Tsien
Journal:  Neuron       Date:  2016-03-16       Impact factor: 17.173

5.  Decreased surface expression of the δ subunit of the GABAA receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome.

Authors:  Nianhui Zhang; Zechun Peng; Xiaoping Tong; A Kerstin Lindemeyer; Yliana Cetina; Christine S Huang; Richard W Olsen; Thomas S Otis; Carolyn R Houser
Journal:  Exp Neurol       Date:  2017-08-16       Impact factor: 5.330

6.  Zinc reduces antiseizure activity of neurosteroids by selective blockade of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  Neuropharmacology       Date:  2018-11-22       Impact factor: 5.250

Review 7.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 8.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 9.  Review of targeted treatments in fragile X syndrome.

Authors:  Andrew Ligsay; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2016-08

10.  Psychosis and catatonia in fragile X: Case report and literature review.

Authors:  Tri Indah Winarni; Andrea Schneider; Neera Ghaziuddin; Andreea Seritan; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.